Trial Profile

Phase III registrational trial of Bevacizumab for diabetic macular edema

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 29 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary)
Indications Diabetic macular oedema
Focus Registrational; Therapeutic Use
Acronyms NORSE 5

Most Recent Events

22 Dec 2021 According to a Outlook Therapeutics media release, the company expects to initiate this study in 2023 if FDA approval is received for the wet AMD indication.
08 Jun 2021 According to an Outlook Therapeutics media release, this study is expected to begin later in calendar 2021 or in early calendar 2022.
16 Feb 2021 According to an Outlook Therapeutics media release, this study is expected to begin later in 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com